![WHO statement on AstraZeneca COVID-19 vaccine safety signals - PAHO/WHO | Pan American Health Organization WHO statement on AstraZeneca COVID-19 vaccine safety signals - PAHO/WHO | Pan American Health Organization](https://www.paho.org/sites/default/files/styles/max_1500x1500/public/card/2021-03/covine-19-vaccine-3-1500x850.jpg?itok=FfcauOGB)
WHO statement on AstraZeneca COVID-19 vaccine safety signals - PAHO/WHO | Pan American Health Organization
![Understanding the blood clot issue behind the AstraZeneca vaccine and its safety - Hamilton Health Sciences Understanding the blood clot issue behind the AstraZeneca vaccine and its safety - Hamilton Health Sciences](https://www.hamiltonhealthsciences.ca/wp-content/uploads/2021/04/CovidStats_07-04-21-final_Page_2-scaled.jpg)
Understanding the blood clot issue behind the AstraZeneca vaccine and its safety - Hamilton Health Sciences
Second dose of AstraZeneca COVID-19 vaccine: FAQs about blood clots, safety, risks and symptoms | The Royal Society of Canada
![COVID 19: Oxford/AstraZeneca vaccine is safe and effective, independent analysis finds | UK News | Sky News COVID 19: Oxford/AstraZeneca vaccine is safe and effective, independent analysis finds | UK News | Sky News](https://e3.365dm.com/20/11/2048x1152/skynews-covid-19-coronavirus_5181340.jpg)
COVID 19: Oxford/AstraZeneca vaccine is safe and effective, independent analysis finds | UK News | Sky News
UK Health Security Agency - Evidence tells us that the AstraZeneca COVID-19 vaccine is very safe and causes few serious side effects. You should still go and get your COVID-19 vaccine when
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://www.thelancet.com/cms/attachment/c0547203-d7c7-4471-bd9b-1440f4613981/gr1_lrg.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![COVID-19: safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 (AstraZeneca/Oxford) COVID-19: safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 (AstraZeneca/Oxford)](https://www.pcronline.com/var/pcrov3/storage/images/media/pcr/publications/illustrations/covid-19/chadox1_figure/13964748-7-eng-GB/Chadox1_figure_imagefull.jpg)
COVID-19: safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 (AstraZeneca/Oxford)
![ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021 | Australian Government Department of Health and Aged Care ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021 | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/news/2021/06/atagi-statement-on-revised-recommendations-on-the-use-of-covid-19-vaccine-astrazeneca-17-june-2021.jpeg?itok=DW5XCPzY)